About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Lepr
leptin receptor
MGI:104993
336 phenotypes from 42 alleles in 74 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Agrptm1(cre)Lowl/Agrp+
Leprtm1.1Chua/Leprtm1.1Chua
involves: 129S6/SvEvTac 		normal nervous system phenotype J:174691
Agrptm1(cre)Lowl/Agrp+
Leprtm1.1Chua/Leprtm1.1Chua
Tg(Pomc1-hrGFP)1Lowl/0
involves: 129S6/SvEvTac * FVB/N 		normal nervous system phenotype J:174691
Leprbrta/Leprbrta
C57BL/6JSfdAnu-Leprbrta/Anu 		hyperglycemia J:104190
infertility J:104190
obese J:104190
Leprdb-1R/Leprdb-1R
involves: D7R75M 		increased body weight J:81149
obese J:81149
LeprDb-2Btlr/Lepr+
C57BL/6J-LeprDb-2Btlr 		increased body weight J:133633
LeprDb-2Btlr/LeprDb-2Btlr
C57BL/6J-LeprDb-2Btlr 		infertility J:133633
obese J:133633
Leprdb-2J/Leprdb-2J
involves: C57BL/6J * STOCK Tyrp1b Whrnwi 		abnormal diestrus J:6157
abnormal hormone level J:6157
abnormal metestrus J:6157
constricted vagina orifice J:6157
decreased follicle stimulating hormone level J:6157
decreased male mating frequency J:6157
female infertility J:6157
small male preputial gland J:6157
small uterus J:6157
Leprdb-3J/Leprdb-3J
129P3/J-Leprdb-3J/J 		abnormal exocrine pancreas morphology J:6337
hyperglycemia J:6337
hypoglycemia J:6337
increased body weight J:6337
increased circulating glucagon level J:6337
increased circulating insulin level J:6337
increased pancreatic alpha cell number J:6337
increased pancreatic beta cell number J:6337
infertility J:6337
obese J:6337
pancreatic islet hyperplasia J:6337
polyphagia J:6337
premature death J:6337
weight loss J:6337
Leprdb-3J/Leprdb-3J
B6.129-Leprdb-3J 		abnormal circulating glucose level J:78850
abnormal circulating insulin level J:78850
abnormal glucose homeostasis J:78850
increased insulin sensitivity J:78850
Leprdb-5J/Leprdb-5J
NOD/ShiLt-Leprdb-5J 		abnormal CD4-positive, alpha beta T cell morphology J:118304
abnormal CD8-positive, alpha beta T cell morphology J:118304
abnormal circulating glucose level J:118305
abnormal pancreatic islet morphology J:118305
degranulated pancreatic beta cells J:118305
normal homeostasis/metabolism phenotype J:118304
hyperglycemia J:118305
increased circulating insulin level J:118305
increased circulating leptin level J:118305
increased percent body fat/body weight J:118305
increased susceptibility to weight gain J:118305
pancreas inflammation J:118305
periinsulitis J:118305
polyphagia J:118305
premature death J:118305
weight loss J:118305
Leprdb-5J/Leprdb-5J
NOD/ShiLtJ-Leprdb-5J/LtJ 		degranulated pancreatic beta cells J:87061
hyperglycemia J:87061
increased circulating insulin level J:87061
obese J:87061
pancreatic islet hyperplasia J:87061
Leprdb-9J/Leprdb-9J
involves: C57BL/6 * CBA * SWR 		abnormal adrenal gland zona reticularis morphology J:129982
abnormal pancreatic beta cell morphology J:129982
absent adrenal medulla J:129982
decreased circulating insulin level J:129982
decreased corpora lutea number J:129982
decreased mature ovarian follicle number J:129982
decreased oocyte number J:129982
degranulated pancreatic beta cells J:129982
enlarged adrenal glands J:129982
hepatic steatosis J:129982
hyperglycemia J:129982
increased body size J:129982
increased liver glycogen level J:129982
reduced female fertility J:129982
Leprdb-ad/Leprdb-ad
Not Specified 		increased body weight J:31691
increased circulating glucose level J:31691
increased circulating insulin level J:31691
increased food intake J:31691
polyuria J:31691
LeprDb-Btlr/Lepr+
C57BL/6J-LeprDb-Btlr 		increased body weight J:133632
LeprDb-Btlr/LeprDb-Btlr
C57BL/6J-LeprDb-Btlr 		hyperglycemia J:133632
infertility J:133632
obese J:133632
Leprdb-lb/Leprdb-lb
C57BL/6NCrl-Leprdb-lb/Crl 		abnormal lipid level J:171755
hepatic steatosis J:171755
increased blood uric acid level J:171755
increased mean systemic arterial blood pressure J:171755
insulin resistance J:171755
obese J:171755
white adipose tissue inflammation J:171755
Leprdb-NCSU/Leprdb-NCSU
involves: CD-1 		female infertility J:60363
increased circulating glucose level J:60363
increased circulating insulin level J:60363
increased circulating leptin level J:60363
increased urine glucose level J:60363
insulin resistance J:60363
male infertility J:60363
obese J:60363
polydipsia J:60363
polyphagia J:60363
premature death J:60363
Leprdb-Nokl/Leprdb-Nokl
C57BL/6N-Leprdb-Nokl 		abnormal carbon dioxide production J:313303
abnormal locomotor circadian rhythm J:313303
abnormal oxygen consumption J:313303
abnormal peptide metabolism J:313303
decreased circulating adiponectin level J:313303
decreased core body temperature J:313303
decreased locomotor activity J:313303
normal homeostasis/metabolism phenotype J:313303
impaired glucose tolerance J:313303
increased body fat mass J:313303
increased circulating cholesterol level J:313303
increased circulating HDL cholesterol level J:313303
increased circulating insulin level J:313303
increased circulating LDL cholesterol level J:313303
increased circulating leptin level J:313303
increased circulating triglyceride level J:313303
increased fasting circulating glucose level J:313303
increased food intake J:313303
increased glycosylated hemoglobin level J:313303
increased gonadal fat pad weight J:313303
increased liver triglyceride level J:313303
increased subcutaneous adipose tissue amount J:313303
increased susceptibility to diet-induced hepatic steatosis J:313303
increased susceptibility to diet-induced non-insulin dependent diabetes J:313303
increased white fat cell size J:313303
male infertility J:313303
obese J:313303
short tail J:313303
Leprdb-rtnd/Leprdb-rtnd
involves: C57BL/6 * CBA/J 		abnormal pancreatic beta cell morphology J:83762
hyperglycemia J:83762
increased circulating insulin level J:83762
obese J:83762
Leprdb/Lepr+
B6.Cg-Dock7m +/+ Leprdb/J 		extended life span J:6081
increased body weight J:82334
Leprdb/Lepr+
involves: C57BLKS/J 		abnormal circulating insulin level J:71934
abnormal glucose homeostasis J:71934
abnormal hormone level J:71934
decreased circulating insulin level J:219658
decreased response to leptin J:71934
enlarged placenta J:219658
impaired glucose tolerance J:71934, J:219658
increased birth weight J:219658
increased body weight J:219658
increased circulating glucose level J:71934
increased circulating leptin level J:219658
increased food intake J:71934
increased susceptibility to weight gain J:71934
increased total body fat amount J:71934
maternal effect J:219658
Leprdb/Leprdb-5J
involves: C57BLKS/J * NOD/ShiLtJ 		obese J:118305
Leprdb/Leprdb-Nokl
B6NTac.Cg-Leprdb Leprdb-Nokl 		abnormal carbon dioxide production J:313303
abnormal locomotor circadian rhythm J:313303
abnormal oxygen consumption J:313303
abnormal peptide metabolism J:313303
decreased circulating adiponectin level J:313303
decreased core body temperature J:313303
decreased locomotor activity J:313303
normal homeostasis/metabolism phenotype J:313303
impaired glucose tolerance J:313303
increased body fat mass J:313303
increased circulating cholesterol level J:313303
increased circulating HDL cholesterol level J:313303
increased circulating insulin level J:313303
increased circulating LDL cholesterol level J:313303
increased circulating leptin level J:313303
increased circulating triglyceride level J:313303
increased fasting circulating glucose level J:313303
increased food intake J:313303
increased glycosylated hemoglobin level J:313303
increased gonadal fat pad weight J:313303
increased liver triglyceride level J:313303
increased subcutaneous adipose tissue amount J:313303
increased susceptibility to diet-induced hepatic steatosis J:313303
increased susceptibility to diet-induced non-insulin dependent diabetes J:313303
increased white fat cell size J:313303
obese J:313303
short tail J:313303
Leprdb/Leprdb
B6.BKS(D)-Leprdb/J 		abnormal behavior J:112820
abnormal response/metabolism to endogenous compounds J:166105
decreased body temperature J:166105
decreased carbon dioxide production J:166105
decreased locomotor activity J:166105
decreased oxygen consumption J:166105
glomerulosclerosis J:160943
impaired glucose tolerance J:166105
insulin resistance J:166105
Leprdb/Leprdb
B6.BKS(D)-Leprdb/JOrlRj 		hepatic steatosis J:277927
increased body weight J:277927
increased cholesterol level J:277927
increased circulating ketone body level J:277927
increased hepatocyte apoptosis J:277927
increased susceptibility to diet-induced obesity J:277927
liver fibrosis J:277927
liver inflammation J:277927
macrovesicular hepatic steatosis J:277927
microvesicular hepatic steatosis J:277927
Leprdb/Leprdb
B6.Cg-Dock7m +/+ Leprdb/J 		abnormal chemokine level J:115772
abnormal circulating cholesterol level J:18161
abnormal circulating lipid level J:18161
abnormal female reproductive system morphology J:82334
abnormal functional residual capacity J:115772
abnormal glucose homeostasis J:82334
abnormal hormone level J:6157
abnormal hypothalamus physiology J:6157
abnormal interleukin level J:115772
abnormal leukocyte morphology J:115772
abnormal lung compliance J:115772
abnormal myocardial fiber morphology J:103063
abnormal respiratory mechanics J:115772
absent estrous cycle J:6157
absent estrus J:82334
anovulation J:82334
constricted vagina orifice J:6157
decreased body length J:82334
decreased circulating adiponectin level J:115772
decreased leukocyte cell number J:115772
decreased male mating frequency J:6157
decreased pulmonary ventilation J:115772
female infertility J:6157, J:82334
heart left ventricle hypertrophy J:103063
hyperglycemia J:18161
increased circulating cholesterol level J:18161
increased circulating glucose level J:82334
increased circulating HDL cholesterol level J:18161
increased circulating insulin level J:82334
increased circulating interleukin-6 level J:115772
increased circulating LDL cholesterol level J:18161
increased circulating leptin level J:82334, J:115772
increased circulating triglyceride level J:18161, J:82334
increased circulating VLDL cholesterol level J:18161
increased metastatic potential J:117826
increased neutrophil cell number J:115772
lung inflammation J:115772
obese J:18161, J:82334, J:103063
polyphagia J:82334
small uterus J:6157
Leprdb/Leprdb
B6NTac.BKS(D)-Leprdb 		abnormal carbon dioxide production J:313303
abnormal locomotor circadian rhythm J:313303
abnormal oxygen consumption J:313303
abnormal peptide metabolism J:313303
decreased core body temperature J:313303
decreased locomotor activity J:313303
normal homeostasis/metabolism phenotype J:313303
impaired glucose tolerance J:313303
increased body fat mass J:313303
increased circulating cholesterol level J:313303
increased circulating HDL cholesterol level J:313303
increased circulating insulin level J:313303
increased circulating LDL cholesterol level J:313303
increased circulating leptin level J:313303
increased circulating triglyceride level J:313303
increased fasting circulating glucose level J:313303
increased food intake J:313303
increased glycosylated hemoglobin level J:313303
increased gonadal fat pad weight J:313303
increased liver triglyceride level J:313303
increased subcutaneous adipose tissue amount J:313303
increased susceptibility to diet-induced hepatic steatosis J:313303
increased susceptibility to diet-induced non-insulin dependent diabetes J:313303
increased white fat cell size J:313303
obese J:313303
short tail J:313303
Leprdb/Leprdb
BKS(D)-Leprdb/JOrlRj 		abnormal blood homeostasis J:357542
hyperglycemia J:357542
increased susceptibility to weight gain J:357542
obese J:357542
Leprdb/Leprdb
BKS.Cg-Dock7m +/+ Leprdb 		abnormal glomerular mesangium morphology J:346348
abnormal podocyte morphology J:346348
abnormal renal glomerulus morphology J:346348
enlarged kidney J:346348
expanded mesangial matrix J:346348
glomerulosclerosis J:346348
hyperglycemia J:346348
increased blood urea nitrogen level J:346348
increased body weight J:346348
increased circulating cholesterol level J:346348
increased circulating creatinine level J:346348
increased circulating insulin level J:346348
increased circulating triglyceride level J:346348
increased glomerular capsule space J:346348
kidney inflammation J:346348
polydipsia J:346348
renal fibrosis J:346348
renal glomerulus hypertrophy J:346348
Leprdb/Leprdb
BKS.Cg-Dock7m +/+ Leprdb/J 		abnormal aorta morphology J:302677
abnormal axon extension J:112680
abnormal axon morphology J:6323
abnormal circulating cholesterol level J:18161
abnormal circulating glucose level J:43162
abnormal circulating lipid level J:18161
abnormal CNS synaptic transmission J:109401
abnormal enzyme/coenzyme activity J:302677
abnormal eye electrophysiology J:103714
abnormal food intake J:43162
abnormal learning/memory/conditioning J:109401
abnormal locomotor circadian rhythm J:91813
abnormal myelin sheath morphology J:6323
abnormal myocardial fiber morphology J:6115
abnormal nerve conduction J:6323
abnormal nervous system morphology J:6323
abnormal spatial learning J:109401
abnormal spatial reference memory J:109401
abnormal vascular development J:6115
absent long-term depression J:109401
albuminuria J:135864
decreased circulating glucose level J:43162, J:91813
decreased circulating insulin level J:43162, J:91813
decreased circulating triglyceride level J:91813
decreased motor neuron number J:6323
decreased prostaglandin level J:185546
decreased urine albumin level J:82491
delayed wound healing J:185546
expanded mesangial matrix J:135864
hyperglycemia J:135864, J:185546
improved glucose tolerance J:43162
increased body weight J:135864
increased circulating cholesterol level J:18161
increased circulating glucose level J:6323
increased circulating HDL cholesterol level J:18161
increased circulating LDL cholesterol level J:18161
increased circulating triglyceride level J:18161
increased circulating VLDL cholesterol level J:18161
increased creatinine clearance J:82491
increased glucagon secretion J:6264
obese J:6323
reduced long-term potentiation J:109401
weight loss J:91813
Leprdb/Leprdb
BKS.Cg-Dock7m +/+ Leprdb/Jcl 		abnormal epididymal fat pad morphology J:110277
abnormal pancreas physiology J:156725
hyperglycemia J:156725
increased circulating insulin level J:156725
increased pancreatic beta cell mass J:156725
increased pancreatic islet cell apoptosis J:156725
Leprdb/Leprdb
BKS.Cg-Dock7m +/+ Leprdb/OlaHsd 		abnormal acute inflammation J:124815
abnormal chemokine secretion J:124815
abnormal digestive system physiology J:124815
abnormal intestinal epithelium morphology J:124815
increased interleukin-6 secretion J:124815
increased susceptibility to endotoxin shock J:124815
liver inflammation J:124815
Leprdb/Leprdb
FVB.BKS-Leprdb 		abnormal circulating glucose level J:78850
abnormal renal glomerulus morphology J:78850
hyperglycemia J:78850
impaired glucose tolerance J:78850
increased circulating insulin level J:78850
increased pancreatic beta cell number J:78850
insulin resistance J:78850
obese J:78850
pancreatic islet hyperplasia J:78850
Leprdb/Leprdb
involves: 129S2/SvPas * C57BL/6 * C57BLKS/J 		abnormal kidney morphology J:127478
abnormal renal glomerulus morphology J:127478
Leprdb/Leprdb
involves: C57BL/6 		abnormal osteoclast differentiation J:60001
abnormal skeleton development J:60001
increased bone volume J:60001
Leprdb/Leprdb
involves: C57BL/6 * C57BLKS/J 		abnormal eating behavior J:164339
abnormal female reproductive system morphology J:164339
abnormal oxygen consumption J:142218
absent estrous cycle J:164339
absent estrus J:164339
decreased body length J:142218, J:164339
decreased lean body mass J:164339
decreased locomotor activity J:142218
female infertility J:142218, J:164339
hyperglycemia J:142218
impaired adaptive thermogenesis J:142218
impaired glucose tolerance J:142218, J:164339
increased body weight J:164339
increased circulating glucose level J:164339
increased circulating insulin level J:164339
increased circulating leptin level J:142218
increased percent body fat/body weight J:142218, J:164339
insulin resistance J:142218, J:164339
obese J:142218
polyphagia J:142218
short femur J:164339
Leprdb/Leprdb
involves: C57BLKS/J 		abnormal adipose tissue morphology J:232827
abnormal aerobic respiration J:106871, J:107138
abnormal blood circulation J:107138
abnormal cardiovascular system physiology J:106871, J:107138
abnormal conditioned taste aversion behavior J:85127
abnormal endometrium morphology J:80996
abnormal glucose homeostasis J:80996, J:107138
abnormal hypothalamus physiology J:1325
abnormal intraocular pressure J:82879
abnormal kidney calyx morphology J:5257
abnormal kidney papilla morphology J:5257
abnormal myocardium layer morphology J:107138
abnormal nucleotide metabolism J:260830
abnormal pancreatic beta cell morphology J:96047
abnormal pancreatic beta cell physiology J:210493
abnormal pancreatic islet morphology J:96047
abnormal renal glomerulus morphology J:5257
abnormal respiratory electron transport chain J:106871
abnormal response to cardiac infarction J:104790
abnormal uterus morphology J:80996
abnormal vascular wound healing J:135034
abnormal white adipose tissue morphology J:260830
cardiac ischemia J:107138
decreased body length J:89242
decreased body temperature J:96047
decreased cardiac muscle contractility J:106871
decreased cardiac output J:106871, J:107138
decreased circulating glucose level J:117919
decreased circulating insulin level J:117919
decreased heart rate J:106871, J:107138
decreased systemic arterial blood pressure J:135034
decreased systemic arterial systolic blood pressure J:107138
decreased uterus weight J:80996
hyperglycemia J:96047, J:104790, J:106597, J:106871, J:117919, J:210493, J:232827
hyperlipidemia J:96047
impaired adaptive thermogenesis J:89242
impaired glucose tolerance J:89242
increased body weight J:5010, J:80996, J:106597
increased circulating cholesterol level J:232827
increased circulating corticosterone level J:89242
increased circulating free fatty acids level J:106871, J:232827
increased circulating glucose level J:5010, J:80996, J:89242
increased circulating insulin level J:5010, J:80996, J:89242, J:104790, J:106597, J:232827
increased circulating leptin level J:89242, J:232827
increased circulating triglyceride level J:232827
increased glycosylated hemoglobin level J:104790
increased kidney weight J:232827
increased left ventricle diastolic pressure J:106871
increased liver weight J:232827
increased susceptibility to autoimmune diabetes J:7005
increased susceptibility to induced morbidity/mortality J:104790
increased total body fat amount J:89242
increased urine protein level J:5257
increased vasoconstriction J:106597
insulin resistance J:117919
obese J:89242, J:96047, J:104790, J:106871, J:232827
polydipsia J:5010
polyphagia J:5010, J:96047
polyuria J:5010
renal glomerular immunoglobulin deposits J:30970
renal glomerular protein deposits J:30970
LeprKK/LeprKK
involves: C57BL/6J * KK/HlLt 		increased body weight J:53637
increased circulating glucose level J:53637
increased circulating insulin level J:53637
increased circulating leptin level J:53637
obese J:53637
Leprm1Anu/Leprm1Anu
C57BL/6JAnu-Leprm1Anu 		obese J:104190
Leprm1Clo/Leprm1Clo
STOCK Leprm1Clo/GrsrJ 		female infertility J:232775
hepatic steatosis J:232775
obese J:232775
pancreatic islet hyperplasia J:232775
reduced male fertility J:232775
Leprm3Btlr/Leprm3Btlr
C57BL/6J-Leprm3Btlr 		normal homeostasis/metabolism phenotype J:140985
infertility J:140985
obese J:140985
Leprm4Btlr/?
C57BL/6J-Leprm4Btlr 		increased body weight J:159354
Leprm5Btlr/Leprm5Btlr
C57BL/6-Leprm5Btlr 		abnormal circadian temperature homeostasis J:166105
abnormal eating behavior J:166105
abnormal response/metabolism to endogenous compounds J:166105
decreased carbon dioxide production J:166105
decreased locomotor activity J:166105
decreased oxygen consumption J:166105
decreased respiratory quotient J:166105
impaired glucose tolerance J:166105
increased body weight J:166105
increased brown adipose tissue amount J:166105
increased circulating insulin level J:166105
increased circulating leptin level J:166105
increased liver weight J:166105
increased mesenteric fat pad weight J:166105
increased omental fat pad weight J:166105
increased total body fat amount J:166105
insulin resistance J:166105
obese J:166105
Leprm6Btlr/Lepr+
C57BL/6J-Leprm6Btlr 		increased body weight J:216794
Leprm6Btlr/Leprm6Btlr
C57BL/6J-Leprm6Btlr 		increased body weight J:216794
Leprm7Btlr/Leprm7Btlr
C57BL/6J-Leprm7Btlr 		decreased cell death J:236685
decreased response to antigen J:236685
increased circulating glucose level J:236685
increased IgE level J:236685
Leprm8Btlr/Leprm8Btlr
C57BL/6J-Leprm8Btlr 		abnormal pelvic girdle bone morphology J:267679
decreased CD8-positive, naive alpha-beta T cell number J:267679
decreased heart rate J:267679
decreased systemic arterial systolic blood pressure J:267679
hepatic steatosis J:267679
impaired balance J:267679
impaired coordination J:267679
increased body fat mass J:267679
increased body weight J:267679
increased effector memory CD4-positive, alpha-beta T cell number J:267679
increased effector memory CD8-positive, alpha-beta T cell number J:267679
increased percent body fat/body weight J:267679
obese J:267679
short tibia J:267679
Leprm9Btlr/Leprm9Btlr
C57BL/6J-Leprm9Btlr 		increased body weight J:272857
Leprm10Btlr/Leprm10Btlr
C57BL/6J-Leprm10Btlr 		increased body weight J:274729
Leprtm1.1Chua/Lepr+
Tg(Gh1-cre)bKnmn/0
involves: 129 * C57BL/6 * FVB 		decreased somatotroph cell number J:173444
normal reproductive system phenotype J:173444
Leprtm1.1Chua/Leprtm1.1Chua
involves: 129 * C57BL/6 		decreased circulating glucose level J:94019
normal growth/size/body region phenotype J:94019
Leprtm1.1Chua/Leprtm1.1Chua
involves: 129 * C57BL/6J * FVB 		no abnormal phenotype detected J:106354
Leprtm1.1Chua/Leprtm1.1Chua
Ntstm1(cre)Mgmj/Nts+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB 		abnormal locomotor activation J:176657
abnormal neuron physiology J:176657
abnormal percent body fat/body weight J:176657
abnormal synaptic dopamine release J:176657
decreased lean body mass J:176657
decreased locomotor activity J:176657
decreased oxygen consumption J:176657
decreased response to leptin J:176657
increased body weight J:176657
increased circulating leptin level J:176657
increased gonadal fat pad weight J:176657
increased total body fat amount J:176657
Leprtm1.1Chua/Leprtm1.1Chua
Pgrtm2(cre)Lyd/Pgr+
involves: 129 * C57BL/6J * FVB/NJ 		abnormal embryo implantation J:324160
abnormal parturition J:324160
decreased litter size J:324160
delayed parturition J:324160
dystocia J:324160
normal embryo phenotype J:324160
normal homeostasis/metabolism phenotype J:324160
pup cannibalization J:324160
reduced female fertility J:324160
normal reproductive system phenotype J:324160
Leprtm1.1Chua/Leprtm1.1Chua
Prlhtm1(cre)Smln/Prlh+
involves: 129 * C57BL/6J 		abnormal body temperature homeostasis J:215557
abnormal response/metabolism to endogenous compounds J:215557
normal behavior/neurological phenotype J:215557
decreased core body temperature J:215557
decreased energy expenditure J:215557
decreased oxygen consumption J:215557
increased body weight J:215557
increased circulating insulin level J:215557
increased circulating leptin level J:215557
increased epididymal fat pad weight J:215557
increased subcutaneous adipose tissue amount J:215557
obese J:215557
Leprtm1.1Chua/Leprtm1.1Chua
Slc17a6tm2(cre)Lowl/Slc17a6+
involves: 129S6/SvEvTac 		normal adipose tissue phenotype J:174691
normal behavior/neurological phenotype J:174691
normal growth/size/body region phenotype J:174691
normal homeostasis/metabolism phenotype J:174691
normal nervous system phenotype J:174691
Leprtm1.1Chua/Leprtm1.1Chua
Slc32a1tm2(cre)Lowl/Slc32a1+
involves: 129S6/SvEvTac 		abnormal circulating glucose level J:174691
abnormal inhibitory postsynaptic currents J:174691
abnormal nervous system electrophysiology J:174691
increased body weight J:174691
increased circulating insulin level J:174691
increased total body fat amount J:174691
polyphagia J:174691
Leprtm1.1Chua/Leprtm1.1Chua
Slc32a1tm2(cre)Lowl/Slc32a1+
Tg(Pomc1-hrGFP)1Lowl/0
involves: 129S6/SvEvTac * FVB/N 		abnormal inhibitory postsynaptic currents J:174691
Leprtm1.1Chua/Leprtm1.1Chua
Tg(Agrp-cre)1Gsb/0
involves: 129 * FVB/N 		decreased liver triglyceride level J:199803
Leprtm1.1Chua/Leprtm1.1Chua
Tg(Gh1-cre)bKnmn/0
involves: 129 * C57BL/6 * FVB 		decreased circulating growth hormone level J:173444
decreased somatotroph cell number J:173444
normal endocrine/exocrine gland phenotype J:173444
normal homeostasis/metabolism phenotype J:173444
increased body weight J:173444
increased circulating leptin level J:173444
increased lean body mass J:173444
increased total body fat amount J:173444
lethality, incomplete penetrance J:173444
obese J:173444
normal reproductive system phenotype J:173444
Leprtm1.1Chua/Leprtm1.1Chua
Tg(Nr5a1-cre)2Lowl/0
involves: 129 * C57BL/6J * FVB 		abnormal energy expenditure J:105327
abnormal fat pad morphology J:105327
abnormal gonadal fat pad morphology J:105327
abnormal nervous system electrophysiology J:105327
abnormal renal fat pad morphology J:105327
increased body weight J:105327
increased circulating leptin level J:105327
increased food intake J:105327
increased susceptibility to diet-induced obesity J:105327
increased total body fat amount J:105327
Leprtm1.1Chua/Leprtm1.1Chua
Tg(Nr5a1-cre)2Lowl/0
Tg(Pomc1-cre)16Lowl/0
involves: 129 * C57BL/6J * FVB 		abnormal fat pad morphology J:105327
abnormal gonadal fat pad morphology J:105327
abnormal mesenteric fat pad morphology J:105327
abnormal renal fat pad morphology J:105327
increased circulating leptin level J:105327
increased total body fat amount J:105327
obese J:105327
Leprtm1.1Chua/Leprtm1.1Chua
Tg(Nr5a1-cre)7Lowl/0
involves: 129 * C57BL/6J * FVB 		increased body weight J:105327
Leprtm1.1Chua/Leprtm1.1Chua
Tg(Pomc1-cre)16Lowl/0
involves: 129 * C57BL/6J * FVB 		abnormal epididymal fat pad morphology J:106354
abnormal fat pad morphology J:105327, J:106354
abnormal gonadal fat pad morphology J:105327
abnormal mesenteric fat pad morphology J:105327, J:106354
abnormal renal fat pad morphology J:105327, J:106354
increased body weight J:105327
increased circulating leptin level J:105327, J:106354
increased total body fat amount J:105327, J:106354
obese J:106354
Leprtm1.1Chua/Leprtm1.1Chua
Tg(Pomc1-cre)16Lowl/0
involves: 129 * FVB 		normal nervous system phenotype J:174691
Leprtm1.1Chua/Leprtm1.1Chua
Tg(Pomc1-cre)16Lowl/0
Tg(Pomc1-hrGFP)1Lowl/0
involves: 129 * FVB 		normal nervous system phenotype J:174691
Leprtm1.1Chua/Leprtm1.1Chua
Tg(Syn1-cre)671Jxm/0
involves: 129 * C57BL/6 * CBA 		abnormal sympathetic nervous system physiology J:145998
decreased circulating adrenaline level J:145998
decreased circulating noradrenaline level J:145998
increased insulin secretion J:145998
Leprtm1.1Chua/Leprtm1.2Chua
Nos1tm1(cre)Mgmj/Nos1+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 		normal behavior/neurological phenotype J:183754
decreased circulating thyroxine level J:183754
decreased locomotor activity J:183754
decreased oxygen consumption J:183754
delayed estrous cycle J:183754
increased body weight J:183754
increased circulating corticosterone level J:183754
increased circulating glucose level J:183754
increased circulating insulin level J:183754
increased circulating leptin level J:183754
increased food intake J:183754
increased total body fat amount J:183754
normal reproductive system phenotype J:183754
Leprtm1.1Rck/Leprtm1.1Rck
involves: 129P2/OlaHsd 		obese J:72241
Leprtm1.1Rll/Lepr+
129P3/J-Leprtm1.1Rll 		increased enterocyte apoptosis J:172012
increased susceptibility to parasitic infection J:172012
Leprtm1.1Rll/Leprtm1.1Rll
129-Leprtm1.1Rll 		normal growth/size/body region phenotype J:173593
normal homeostasis/metabolism phenotype J:173593
Leprtm1.1Rll/Leprtm1.1Rll
129P3/J-Leprtm1.1Rll 		increased enterocyte apoptosis J:172012
increased susceptibility to parasitic infection J:172012
Leprtm1.2Chua/Leprtm1.2Chua
involves: 129 * C57BL/6 		abnormal glucose homeostasis J:94019
hyperglycemia J:94019
impaired adaptive thermogenesis J:94019
increased circulating insulin level J:94019
increased susceptibility to weight gain J:94019
infertility J:94019
obese J:94019
polyphagia J:94019
Leprtm1.2Chua/Leprtm1.2Chua
involves: 129 * C57BL/6 * CBA 		abnormal inhibitory postsynaptic currents J:174691
increased body weight J:174691
Leprtm1.2Chua/Leprtm1.2Chua
involves: 129 * C57BL/6J * FVB/N 		obese J:106354
Leprtm1b(EUCOMM)Wtsi/Leprtm1b(EUCOMM)Wtsi
C57BL/6N-Leprtm1b(EUCOMM)Wtsi/H 		abnormal bone structure J:211773
abnormal gait J:211773
abnormal locomotor behavior J:211773
decreased bone mineral content J:211773
decreased bone mineral density J:211773
decreased circulating chloride level J:211773
decreased exploration in new environment J:211773
decreased heart weight J:211773
decreased lean body mass J:211773
decreased leukocyte cell number J:211773
decreased locomotor activity J:211773
decreased lymphocyte cell number J:211773
decreased spleen weight J:211773
enlarged liver J:211773
female infertility J:211773
impaired righting response J:211773
increased anxiety-related response J:211773
increased circulating alanine transaminase level J:211773
increased circulating alkaline phosphatase level J:211773
increased circulating amylase level J:211773
increased circulating aspartate transaminase level J:211773
increased circulating calcium level J:211773
increased circulating cholesterol level J:211773
increased circulating fructosamine level J:211773
increased circulating glucose level J:211773
increased circulating HDL cholesterol level J:211773
increased circulating iron level J:211773
increased circulating phosphate level J:211773
increased circulating potassium level J:211773
increased circulating serum albumin level J:211773
increased circulating total protein level J:211773
increased circulating triglyceride level J:211773
increased eosinophil cell number J:211773
increased hematocrit J:211773
increased hemoglobin content J:211773
increased mean corpuscular hemoglobin J:211773
increased mean corpuscular volume J:211773
increased mean platelet volume J:211773
increased monocyte cell number J:211773
increased neutrophil cell number J:211773
increased red blood cell distribution width J:211773
increased total body fat amount J:211773
limb grasping J:211773
male infertility J:211773
small seminal vesicle J:211773
thrombocytopenia J:211773
tremors J:211773
trunk curl J:211773
Leprtm1Chua/Leprtm1Chua
involves: 129 * C57BL/6 		abnormal glucose homeostasis J:94019
impaired adaptive thermogenesis J:94019
increased circulating glucose level J:94019
increased circulating insulin level J:94019
increased circulating leptin level J:94019
increased susceptibility to weight gain J:94019
infertility J:94019
obese J:94019
polyphagia J:94019
Leprtm1Jke/Leprtm1Jke
involves: 129X1/SvJ 		hyperglycemia J:216393
increased circulating insulin level J:216393
increased liver triglyceride level J:216393
increased susceptibility to non-insulin-dependent diabetes J:216393
obese J:216393
Leprtm1Jke/Leprtm1Jke
involves: 129X1/SvJ * C57BL/6J 		abnormal eating behavior J:184572
abnormal gluconeogenesis J:184572
abnormal glucose homeostasis J:184572
decreased carbon dioxide production J:184572
decreased locomotor activity J:184572
decreased oxygen consumption J:184572
decreased respiratory quotient J:184572
hyperglycemia J:184572
increased circulating cholesterol level J:184572
increased circulating glucagon level J:184572
increased circulating insulin level J:184572
increased circulating leptin level J:184572
increased circulating triglyceride level J:184572
increased insulin secretion J:184572
increased insulin sensitivity J:184572
increased liver triglyceride level J:184572
obese J:184572
Leprtm1Jke/Leprtm1Jke
Tg(Pomc1-cre)16Lowl/0
involves: 129X1/SvJ * C57BL/6J * FVB/N 		abnormal eating behavior J:184572
abnormal glucose homeostasis J:184572
decreased body weight J:184572
decreased carbon dioxide production J:184572
decreased circulating cholesterol level J:184572
decreased circulating glucose level J:184572
decreased circulating insulin level J:184572
decreased circulating triglyceride level J:184572
decreased liver triglyceride level J:184572
decreased oxygen consumption J:184572
decreased total body fat amount J:184572
normal homeostasis/metabolism phenotype J:184572
hyperactivity J:184572
increased carbon dioxide production J:184572
increased circulating cholesterol level J:184572
increased circulating insulin level J:184572
increased circulating leptin level J:184572
increased circulating triglyceride level J:184572
increased insulin secretion J:184572
increased insulin sensitivity J:184572
increased liver triglyceride level J:184572
increased oxygen consumption J:184572
increased respiratory quotient J:184572
increased total body fat amount J:184572
obese J:184572
Leprtm1Mgmj/Lepr+
B6.129-Leprtm1Mgmj 		increased body weight J:82334
Leprtm1Mgmj/Leprtm1Mgmj
B6.129-Leprtm1Mgmj 		abnormal energy expenditure J:82334
abnormal glucose homeostasis J:82334
abnormal lactation J:82334
abnormal vascular wound healing J:135034
decreased systemic arterial blood pressure J:135034
delayed estrous cycle J:82334
increased body length J:82334
increased circulating glucose level J:82334
increased circulating insulin level J:82334
increased circulating leptin level J:82334
increased circulating triglyceride level J:82334
obese J:82334
polyphagia J:82334
reduced female fertility J:82334
Leprtm1Mgmj/Leprtm1Mgmj
involves: 129 		absent estrous cycle J:164339
absent estrus J:164339
female infertility J:164339
Leprtm1Rck/Leprtm1.1Rck
Tg(Alb1-cre)1Rck/0
involves: 129P2/OlaHsd * C57BL/6 * CBA 		no abnormal phenotype detected J:72241
Leprtm1Rck/Leprtm1.1Rck
Tg(Syn1-cre)671Jxm/0
involves: 129P2/OlaHsd * C57BL/6 * CBA 		abnormal body composition J:72241
hepatic steatosis J:72241
hyperglycemia J:72241
increased body weight J:72241
increased circulating insulin level J:72241
increased circulating leptin level J:72241
increased total body fat amount J:72241
Leprtm1Rck/Leprtm1Rck
involves: 129 		no abnormal phenotype detected J:72241
Leprtm1Rck/Leprtm1Rck
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
involves: 129 * C57BL/6 		decreased physiological sensitivity to xenobiotic J:344866
increased circulating leptin level J:344866
obese J:344866
Leprtm1Yli/Leprtm1Yli
B6.129-Leprtm1Yli 		abnormal body temperature J:142218
abnormal circulating glucose level J:142218
abnormal oxygen consumption J:142218
decreased locomotor activity J:142218
female infertility J:142218
impaired adaptive thermogenesis J:142218
impaired glucose tolerance J:142218
increased body length J:142218
increased body weight J:142218
increased circulating insulin level J:142218
increased circulating leptin level J:142218
increased percent body fat/body weight J:142218
insulin resistance J:142218
male infertility J:142218
obese J:142218
polyphagia J:142218
Leprtm2Mgmj/Lepr+
B6.Cg-Leprtm2Mgmj 		decreased circulating insulin level J:122056
Leprtm2Mgmj/Leprtm2Mgmj
B6.Cg-Leprtm2Mgmj 		abnormal fat pad morphology J:122056
decreased body weight J:122056
decreased circulating insulin level J:122056
decreased circulating leptin level J:122056
decreased gonadal fat pad weight J:122056
Leprtm2Mgmj/Leprtm2Mgmj
Not Specified 		decreased insulin secretion J:145998
Leprtm2Yli/Leprtm2Yli
B6.129-Leprtm2Yli 		abnormal body temperature J:142218
abnormal circulating glucose level J:142218
abnormal oxygen consumption J:142218
decreased locomotor activity J:142218
impaired adaptive thermogenesis J:142218
impaired glucose tolerance J:142218
increased body length J:142218
increased body weight J:142218
increased circulating insulin level J:142218
increased circulating leptin level J:142218
increased percent body fat/body weight J:142218
insulin resistance J:142218
male infertility J:142218
obese J:142218
polyphagia J:142218
reduced female fertility J:142218
Leprtm3(cre)Mgmj/Leprtm3(cre)Mgmj
involves: 129S1/Sv * 129X1/SvJ 		normal growth/size/body region phenotype J:131433
Leprtm3.1Yli/Lepr+
B6.129-Leprtm3.1Yli 		increased percent body fat/body weight J:161732
increased susceptibility to age related obesity J:161732
Leprtm3.1Yli/Leprtm3.1Yli
B6.129-Leprtm3.1Yli 		abnormal food intake J:161732
abnormal locomotor activation J:161732
abnormal oxygen consumption J:161732
abnormal response/metabolism to endogenous compounds J:161732
decreased circulating leptin level J:161732
increased circulating glucose level J:161732
increased circulating insulin level J:161732
increased circulating leptin level J:161732
increased percent body fat/body weight J:161732
increased susceptibility to age related obesity J:161732
increased susceptibility to diet-induced obesity J:161732
Leprtm4Mgmj/Leprtm4Mgmj
B6.Cg-Leprtm4Mgmj 		abnormal eating behavior J:164339
abnormal female reproductive system morphology J:164339
absent estrous cycle J:164339
absent estrus J:164339
decreased body length J:164339
decreased body temperature J:164339
decreased CD4-positive, alpha-beta T cell number J:164339
decreased lean body mass J:164339
decreased splenocyte number J:164339
decreased T cell proliferation J:164339
female infertility J:164339
impaired glucose tolerance J:164339
increased body weight J:164339
increased circulating glucose level J:164339
increased circulating insulin level J:164339
increased percent body fat/body weight J:164339
insulin resistance J:164339
short femur J:164339
Leprtm5Mgmj/Leprtm5Mgmj
B6.129-Leprtm5Mgmj 		abnormal eating behavior J:179119
abnormal estrous cycle J:179119
abnormal insulin secretion J:221245
increased body weight J:179119
increased circulating leptin level J:179119
increased total body fat amount J:179119
insulin resistance J:221245
normal reproductive system phenotype J:179119
Leprtm5Mgmj/Leprtm5Mgmj
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J 		delayed estrus J:221245
increased body weight J:221245
increased circulating leptin level J:221245
increased food intake J:221245
increased oxygen consumption J:221245
increased total body fat amount J:221245
normal reproductive system phenotype J:221245
Tg(Apoe-Lepr)1Kry/0
involves: C57BL/6J 		normal homeostasis/metabolism phenotype J:88655
normal skeleton phenotype J:88655
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
12/10/2024
MGI 6.24 		The Jackson Laboratory